Back

Do we need trials of combination pharmacotherapy?

24 May 2022 (09:00 - 09:15)
Organised by:
Congress Presentation Part of: What next for trials in heart failure with preserved ejection fraction? Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Naoki Sato

Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi (Japan)

3 More presentations in this session

Presentation thumbnail
Similarities and differences between SGLT2i trials in HFpEF
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Do we need trials to account for sex differences in HFpEF?
Professor C. Lam (Singapore, SG)
Slides Video
Presentation thumbnail
What next for trials in heart failure with preserved ejection fraction? - discussion.
Video

Access the full session

Session thumbnail
What next for trials in heart failure with preserved ejection fraction?
Video

The Event

Event poster

Heart Failure 2022

24 May 2022 09:00 CET
You may be interested in
thumbnail
Congress Presentation
An algorithm for treatment of HFpEF and obesity: SGLT2i? GLP-1RA? or both?
13 May 2024
thumbnail
Congress Presentation
Fixed dose combinations and deprescribing in heart failure
21 May 2023
thumbnail
Congress Presentation
Estimating composite benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction
23 May 2022
thumbnail
Congress Session
Late-Breaking Clinical Trials: advances in heart failure care
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources